Daniel A. Grande, Ph.D., director of the orthopedic research laboratory at the Feinstein Institute, and Todd Goldstein, an investigator at the Feinstein Institute, part of the North Shore-LIJ Health System, with their MakerBot Replicator desktop 3-D printer that they used to 3-D print cartilage to repair tracheal damage.
January 27, 2015 — Three-dimensional (3-D) printing can effectively create a biodegradable tracheal segment containing a patient’s own cells for use in complex tracheal reconstruction, according to a proof of concept study abstract released at the 51st Annual Meeting of The Society of Thoracic Surgeons.
Traditional treatments for tracheal diseases such as stenosis or malacia (abnormal softening of the tissue) usually involve removal of the affected tracheal segment.
“Three-dimensional printing and tissue engineering has the potential for creation of a custom-designed tracheal replacement prosthesis in the lab so that the affected tracheal segment can be ‘swapped out’ instead of removed,” said lead author Todd Goldstein, Ph.D., of the Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System in New York. “Making a windpipe or trachea is uncharted territory. It has to be rigid enough to withstand coughs, sneezes and other shifts in pressure, yet flexible enough to allow the neck to move freely. With 3-D printing, we were able to construct 3-D printed scaffolding that the surgeons could immediately examine and then we could work together in real time to modify the designs.”
Goldstein and colleagues used a custom-designed MakerBot Replicator 2X Experimental 3-D printer that had been modified by engineers to enable printing of living cells. The printer produces a biodegradable scaffold that can be combined with living cells to create a tracheal segment. The size and shape of the scaffold can be customized for each patient. This is a first for medical research where regular MakerBot PLA Filament was used to 3-D print a custom tracheal scaffolding, which was combined with living cells to create a tracheal segment.
“MakerBot was extremely helpful and consulted on optimizing our design files so they would print better and provided advice on how to modify the MakerBot Replicator 2X Experimental 3-D Printer to print with PLA and the biomaterial,” said Goldstein. “We actually found designs to modify the printer on MakerBot’s Thingiverse website to print PLA with one extruder and the biomaterial with the other extruder. We 3-D-printed the needed parts with our other MakerBot Replicator Desktop 3-D Printer, and used them to modify the MakerBot Replicator 2X Experimental 3-D Printer so that we could better iterate and test our ideas.”
For their study, the researchers made three types of printed segments: empty segments, segments without cells (controls) and segments that had been combined with living cells. The bio-printed cells were tested for viability, proliferation (cell growth and division) and gene expression. The researchers found that the cells survived the printing process, were able to continue dividing and produced the cellular properties expected in healthy tracheal cartilage.
“Our results show that three-dimensional printing can be combined with tissue engineering to effectively produce a partial tracheal replacement graft in vitro,” said Goldstein. “Our data demonstrate that the cartilage cells seeded on the graft retain their biological capability and were able to proliferate at the same rate as native cells.”
The authors said that 3-D printing has the potential to revolutionize medicine; patients are already seeing benefits from the technology in the area of customized prosthetics for limb replacement. Reconstructive craniofacial and cardiothoracic surgeons also have been using 3-D printers to build models for more precise surgical planning.
“We think the next phase will be integrating three-dimensional printing and tissue engineering to produce customized biological replacement parts,” said Goldstein. “While further development is necessary before a clinical trial would be viable, our results show that 3-D printing technology is a feasible alternative to traditional treatments.”
3-D printed tissue is not yet approved by the U.S. Food and Drug Administration.
For more information: www.sts.org